Adamas Announces New Employment Inducement Grant
March 06 2020 - 4:39PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the compensation committee of the company’s board of directors
granted six new employees the option to purchase an aggregate of
70,000 shares of the company’s common stock, at a per share
exercise price of $3.89, the closing trading price on March 6, and
restricted stock units to acquire 35,000 shares of the company’s
common stock. The stock options and restricted stock units vest
over four years and were granted pursuant to the Adamas
Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by
the company's board of directors in March 2016 under Rule
5653(c)(4) of the Nasdaq Global Market for equity grants to induce
new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
At Adamas, our purpose and vision are clear:
deliver innovative medicines that make a clinically meaningful
difference for patients, caregivers and society. We are a
fully-integrated company focused on growing a portfolio of
therapies to address a range of neurological diseases. In 2018,
Adamas successfully launched GOCOVRI® (amantadine) extended-release
capsules, the first and only FDA-approved medicine for the
treatment of dyskinesia in patients with Parkinson’s disease
receiving levodopa-based therapy, with or without concomitant
dopaminergic medications. GOCOVRI is also the only medicine
clinically proven to reduce both dyskinesia and OFF. For more
information, please visit www.adamaspharma.com.
Contact:
Investors:Peter VozzoWestwicke Partners
443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President, Communications &
Engagement 510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024